Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 dichloride re-treatment safety study in castration-resistant prostate cancer with bone metastases
2013-003046-17Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2013
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), sponsored by Bayer. Primary endpoint: Number of participants with treatment-related adverse events or serious adverse events. Started Oct 2013; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2013-003046-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003046-17.